ES2394448T3 - Vacuna contra VPH16 yVPH18 y al menos otro tipo de VPH seleccionado de entre VPH 31, 45 o 52 - Google Patents

Vacuna contra VPH16 yVPH18 y al menos otro tipo de VPH seleccionado de entre VPH 31, 45 o 52 Download PDF

Info

Publication number
ES2394448T3
ES2394448T3 ES05757953T ES05757953T ES2394448T3 ES 2394448 T3 ES2394448 T3 ES 2394448T3 ES 05757953 T ES05757953 T ES 05757953T ES 05757953 T ES05757953 T ES 05757953T ES 2394448 T3 ES2394448 T3 ES 2394448T3
Authority
ES
Spain
Prior art keywords
hpv
plv
type
vaccine
types
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05757953T
Other languages
English (en)
Spanish (es)
Inventor
Sergeglaxosmithkline Biologicals S.A. Debrus
Marie-Therese Martin
Robert Johnglaxosmithkline Stephen
Jeanglaxosmithkline Biologicals S.A. Stephenne
Martine Anne Cécile WETTENDORFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application granted granted Critical
Publication of ES2394448T3 publication Critical patent/ES2394448T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES05757953T 2004-06-16 2005-06-14 Vacuna contra VPH16 yVPH18 y al menos otro tipo de VPH seleccionado de entre VPH 31, 45 o 52 Active ES2394448T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
GB0413510 2004-06-16
US114301 2005-04-26
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (1)

Publication Number Publication Date
ES2394448T3 true ES2394448T3 (es) 2013-01-31

Family

ID=32750044

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05757953T Active ES2394448T3 (es) 2004-06-16 2005-06-14 Vacuna contra VPH16 yVPH18 y al menos otro tipo de VPH seleccionado de entre VPH 31, 45 o 52

Country Status (15)

Country Link
JP (1) JP2012102132A (nl)
KR (1) KR101359943B1 (nl)
CN (1) CN1976718B (nl)
CY (1) CY1113830T1 (nl)
DK (1) DK1758609T3 (nl)
ES (1) ES2394448T3 (nl)
GB (1) GB0413510D0 (nl)
HR (1) HRP20120930T1 (nl)
HU (3) HUS1500061I1 (nl)
LT (1) LTC1758609I2 (nl)
NL (3) NL300773I2 (nl)
PT (1) PT1758609E (nl)
SI (1) SI1758609T1 (nl)
TW (1) TW200612983A (nl)
ZA (1) ZA200610057B (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107080833A (zh) * 2009-04-10 2017-08-22 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒（hpv）疫苗的乳头状瘤病毒样颗粒（vlp）
WO2012006727A1 (en) * 2010-07-15 2012-01-19 British Columbia Cancer Agency Branch Human papillomavirus e7 antigen compositions and uses thereof
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN114716560B (zh) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN114716561B (zh) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
HUS1500061I1 (hu) 2016-01-28
PT1758609E (pt) 2012-12-21
NL300771I2 (nl) 2015-12-29
NL300773I1 (nl) 2015-12-29
HUS1500060I1 (hu) 2017-10-30
NL300774I2 (nl) 2015-12-29
DK1758609T3 (da) 2012-12-10
ZA200610057B (en) 2008-02-27
HRP20120930T1 (hr) 2012-12-31
CY1113830T1 (el) 2016-06-22
NL300771I1 (nl) 2015-12-29
KR20120123617A (ko) 2012-11-08
NL300773I2 (nl) 2015-12-29
GB0413510D0 (en) 2004-07-21
NL300774I1 (nl) 2015-12-29
HUS1500059I1 (hu) 2017-10-30
TW200612983A (en) 2006-05-01
JP2012102132A (ja) 2012-05-31
CN1976718B (zh) 2012-10-10
KR101359943B1 (ko) 2014-02-10
SI1758609T1 (sl) 2013-01-31
LTC1758609I2 (lt) 2017-05-10
CN1976718A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
US20050287161A1 (en) Vaccine
ES2394448T3 (es) Vacuna contra VPH16 yVPH18 y al menos otro tipo de VPH seleccionado de entre VPH 31, 45 o 52
EP1758609B1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US20090181052A1 (en) Vaccine
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7858098B2 (en) Vaccine
AU2006239471A1 (en) Vaccine
ES2361913T3 (es) Uso de hpv16 y hpv18 como vacunas con uno o más oncógenos de los tipos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
BRPI0610032A2 (pt) uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit
BRPI0610396A2 (pt) vacina de hpv multivalente, métodos para proteger um paciente contra a infecção, para prevenir ou reduzir a freqüênca de anormalidades citológicas em um paciente, para prevenir a formação de lesões cin histologicamente confirmadas e para fabricar a vacina, e, usos de uma composição, de uma vacina e de uma composição de vacina